Acute Coronary Syndrom
Conditions
Brief summary
A multinational, prospective and observational study that will assess the management of ACS in real-life practices in Middle East North Africa area.
Detailed description
The aim of this Middle Eastern and African study is to describe the short- and long-term (i.e. up to 3 years following the index event) management in patients hospitalized for an Acute Coronary Syndrome and pharmacological management patterns in a 'real-life' setting. The TOURACO observational study will include not only hospitals with cardiac intervention facilities but also regional and community-type hospitals that have limited (if at all) cardiac intervention facilities. The treatments prescription will be left to the investigator discretion, and will be used in accordance with the local label of each country. Off-label medication is not authorized in TOURACO study.
Interventions
OTHERNon-Interventional Study
Non-Interventional Study
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Patients presenting to the emergency room (or equivalent) and diagnosed with UA, STEMI or NSTEMI will be eligible to participate if all the following criteria apply: 1. Provision of subject informed consent. 2. Contact Order Form has been provided. 3. Female and/or male aged 18 years and over. 4. Diagnosis of STEMI, NSTEMI or UA using the following definitions: Criteria for STEMI diagnosis : 1. History of chest pain/discomfort, and 2. Persistent ST-segment elevation (\> 30 min) of ≥ 0.1 mV in 2 or more contiguous ECG leads or presumed new left bundle branch block (LBBB) on admission, and 3. Elevation of cardiac biomarkers (CK-MB, troponins): at least one value above the 99th percentile of the upper reference limit. Criteria for NSTEMI diagnosis : (a) History of chest pain/discomfort, and (d) Lack of persistent ST-segment elevation, LBBB or intraventricular conduction disturbances, and (e) Elevation of cardiac biomarkers (CK-MB, troponins): at least one value above the 99th percentile of the upper reference limit. Criteria for Unstable Angina diagnosis : 1. Symptoms of angina at rest or on minimal exercise, and 2. (Transient) ST-T changes, and 3. No significant increase in biomarkers of necrosis but objective evidence of ischemia by non-invasive imaging or significant coronary stenosis (at angiography). 5. Hospitalized within 24 hours of onset of symptoms during the current episode\* or transferred from another hospital within 24 hours of the onset of symptoms\*\*. * In case of intermittent symptoms, the symptoms onset is that of the last episode \*\* If the referred hospital can get the initial data of the patient from the transferring hospital, transferring period is not considered as a limitation for patient initiation
Exclusion criteria
Patients will not be eligible to participate if any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antithrombotic includinhg Dual Antiplatelet(DAPT) Treatment patterns | 1 Month | Prescription of Antithrombotic including Dual Antiplatelet(DAPT) Treatment patterns at one month of follow-up after discharge from hospital, then confirm whether it is against international guidelines (ESC or ACC guidelines or against local guidelines when the international one are not applicable) |
| Antihypertensive as apart of ACS Treatment patterns | 1 Month | Prescription of Antihypertensive as apart of ACS Treatment patterns at one month of follow-up after discharge from hospital, then confirm whether it is against international guidelines (ESC or ACC guidelines or against local guidelines when the international one are not applicable) |
| Diabetic lowering agents as a part of ACS Treatment patterns in the ACS patients with Diabetes including Type 2 DM | 1 Month | Prescription of Diabetic lowering agents as a part of ACS Treatment patterns in the ACS patients with Diabetes including Type 2 DM at one month of follow-up after discharge from hospital, then confirm whether it is against international guidelines (ESC or ACC guidelines or against local guidelines when the international one are not applicable) |
| Cholesterol lowering agents including statins as a part of ACS Treatment patterns | 1 Month | Prescription of cholesterol lowering agents including statins as a part of ACS Treatment patterns at one month of follow-up after discharge from hospital, then confirm whether it is against international guidelines (ESC or ACC guidelines or against local guidelines when the international one are not applicable) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diabetic lowering agents as a part of ACS Treatment patterns in the ACS patients with Diabetes including Type 2 DM | 6,12,24 & 36 Months | Prescription of Diabetic lowering agents as a part of ACS Treatment patterns in the ACS patients with Diabetes including Type 2 DM at one month of follow-up after discharge from hospital, then confirm whether it is against international guidelines (ESC or ACC guidelines or against local guidelines when the international one are not applicable) |
| Antithrombotic includinhg Dual Antiplatelet(DAPT) Treatment patterns | 6 Month | Prescription of Antithrombotic including Dual Antiplatelet(DAPT) Treatment patterns at one month of follow-up after discharge from hospital, then confirm whether it is against international guidelines (ESC or ACC guidelines or against local guidelines when the international one are not applicable) |
| Cholesterol lowering agents including statins as a part of ACS Treatment patterns | 6,12,24 & 36 Months | Prescription of cholesterol lowering agents including statins as a part of ACS Treatment patterns at one month of follow-up after discharge from hospital, then confirm whether it is against international guidelines (ESC or ACC guidelines or against local guidelines when the international one are not applicable) |
| level of control of the different ACS related risk factor | 1,6,12,24 & 36 Month | Level of control of ACS risk factors (diabetes, HT and dyslipidemia) at intrahospital period (from the first contact till discharge), and at 6 months of follow up. At 12, 24 and 36 months, the level will be measured if the patient comes for a planned visit. |
| Deviation of the treatment patterns of ACS | 3 Years | Deviation of the treatment patterns of ACS against what is recommended in the local guidelines for the management of ACS at the different time intervals |
| Antihypertensive as apart of ACS Treatment patterns | 6,12,24 & 36 Months | Prescription of Antihypertensive as apart of ACS Treatment patterns at one month of follow-up after discharge from hospital, then confirm whether it is against international guidelines (ESC or ACC guidelines or against local guidelines when the international one are not applicable) |
Countries
Qatar
Outcome results
None listed